(4-Chloro-2-fluoro-phenyl)-[6-methoxy-7-(2-morpholin-4-yl-ethoxy)-quinazolin-4-yl]-amine

ID: ALA25610

Chembl Id: CHEMBL25610

PubChem CID: 5329019

Max Phase: Preclinical

Molecular Formula: C21H22ClFN4O3

Molecular Weight: 432.88

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCN1CCOCC1

Standard InChI:  InChI=1S/C21H22ClFN4O3/c1-28-19-11-15-18(12-20(19)30-9-6-27-4-7-29-8-5-27)24-13-25-21(15)26-17-3-2-14(22)10-16(17)23/h2-3,10-13H,4-9H2,1H3,(H,24,25,26)

Standard InChI Key:  WOSBEBRTYHKLTR-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA25610

   Anilinoquinazoline deriv. 21

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 432.88

Molecular Weight (Monoisotopic): 432.1364

AlogP: 3.89

#Rotatable Bonds: 7

Polar Surface Area: 68.74

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 6.20

CX LogP: 3.69

CX LogD: 3.66

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.61

Np Likeness Score: -1.75

References

1. Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO..  (2002)  Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.,  45  (6): [PMID:11881999] [10.1021/jm011022e]

2. Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Lambert-van der Brempt C..  (1999)  Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.,  42  (26): [PMID:10639280] [10.1021/jm990345w]

Source

Source(1):

• Scientific Literature